Why some people don't lose weight on Mounjaro — and what can change

Six weeks in with barely anything to show on the scales

This is probably the situation you recognise. You ordered Mounjaro, went through the clinical assessment, and your plain box arrived via DPD with the KwikPen nestled inside. You started the injections, you noticed the appetite shift, then you stepped on the scales and the number barely moved. It is disheartening, and it is also fairly common in the early weeks.

The 2.5 mg starting dose exists so your digestive system can settle into treatment, not to produce measurable weight loss. Many people who later lose substantial weight see little change in the first four to eight weeks. That is not failure; it is physiology. The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks, a reminder that tirzepatide works over months, not a fortnight. If you want to understand the biological reasons appetite suppression and weight loss happen at all, this overview of how tirzepatide acts on GIP and GLP-1 receptors is a useful starting point. Researchers are also exploring how these mechanisms extend beyond weight loss, including how tirzepatide may benefit people living with hidradenitis suppurativa, a condition closely linked to metabolic and inflammatory factors.

Patience at this stage is genuinely warranted. Switching to a higher dose before your prescriber advises it will not necessarily speed things up and does increase the risk of side effects. Work with the schedule your prescriber set, and flag your concerns at your next review rather than adjusting independently.

When the dose, diet or daily habits are the sticking point

Once past the starter phase, a slow response often has a traceable cause. Caloric intake is the most straightforward one. Mounjaro reduces appetite significantly in most people, but "significantly" is not "completely". If portions have crept back up, or if calorie-dense foods are filling the reduced appetite space, the energy deficit the medicine creates can be smaller than expected. A practical guide to eating patterns while on Mounjaro covers this in more detail.

Protein intake deserves particular mention. On a reduced-calorie diet alongside a GLP-1 or dual-agonist medicine, keeping protein adequate helps preserve muscle mass, and muscle burns more energy at rest than fat does. People who eat very little protein while losing weight tend to lose more muscle alongside fat, which gradually slows the metabolic rate and makes further weight loss harder.

Activity level matters too, though not always in the way people assume. Formal exercise burns calories, but low-level daily movement (walking, standing, not being static for hours) accounts for a surprisingly large share of daily energy expenditure. A look at strategies for improving results on tirzepatide addresses both diet and movement in more detail.

Sleep and stress are underrated. Consistently poor sleep raises ghrelin (a hunger hormone) and reduces leptin (a fullness signal), partly counteracting what Mounjaro is trying to do. High chronic stress drives cortisol, which promotes fat storage around the abdomen. Neither of these is a moral failing; they are physiology, and a prescriber can help you think through whether they are a factor.

Medical and pharmacological reasons for a blunted response

Some people have underlying conditions that genuinely slow weight loss regardless of the medicine. Hypothyroidism that is undertreated is a classic example, even mild thyroid underactivity reduces the metabolic rate and can substantially blunt results. Polycystic ovary syndrome (PCOS), insulin resistance and certain adrenal conditions can all make weight management harder.

Medicines can interfere too. Corticosteroids (for asthma, inflammatory conditions, skin problems), some antidepressants, antipsychotics, beta-blockers and insulin can each promote weight gain or prevent loss. This does not mean those medicines should be stopped (they often cannot be) but it is worth telling your prescriber exactly what else you are taking so the picture is complete. The NHS tirzepatide medicines page lists known interactions and is worth reading alongside your patient information leaflet.

There is also genuine biological variation in how strongly individuals respond to tirzepatide. SURMOUNT-1 enrolled thousands of participants and the distribution of weight loss was wide, a small subset lost less than five percent despite reaching the highest dose. If that is your situation after six months at the highest tolerated dose, NICE guidance (TA1026) sets out that continuing treatment should be reviewed. Your prescriber is the right person to have that conversation with, not a forum. You can read more about what poor response to Mounjaro actually means clinically and what options exist.

When to ask for a clinical review rather than just waiting

If you have been on a therapeutic dose (not 2.5 mg) for at least two months and have seen no movement on the scales despite genuine effort with diet and activity, a clinical review is the right next step. A prescriber can look at your full medication list, thyroid function if it has not been checked recently, and whether there are lifestyle factors that can realistically be adjusted. They can also consider whether a dose increase is appropriate, or whether a different approach makes more sense for you.

Cost sometimes makes people hesitant to raise concerns. It is worth knowing that at nume, the price you pay covers ongoing clinical support, not just the initial consultation, our prescribers are there for follow-up, not just sign-off. If cost comparisons between providers are something you want to understand before or during treatment, a breakdown of how Mounjaro pricing works across UK private providers puts the figures in context. For a broader look at what private weight-loss treatment involves, our treatment overview explains the options.

Non-response is not a sign that you are beyond help. It is a clinical signal that something in the picture needs adjusting. The right response is a conversation with a prescriber, not a higher dose ordered without review. If you would like that conversation, checking your eligibility with our clinical team is where to start.